Navigation Links
Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology
Date:5/24/2013

Madison, WI (PRWEB) May 24, 2013

Quincy Bioscience, a leading research company committed to the discovery and development of calcium-binding proteins to support healthy living, is pleased to announce publication of safety assessment study of apoaequorin in Food and Chemical Toxicology, an international journal published for the British Industrial Biological Research Association.

The objective of the study was to investigate potential adverse effects, if any, of apoaequorin, in rats following subchronic administration. Based on the results of this study, the No Observed-Adverse-Effect Level (NOAEL) for apoaequorin was determined as 666.7 mg/kg bw/day, the highest dose tested. Administration of the apoaequorin preparation did not result in any mortality. There were no further clinical or opthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology, or histopathological changes attributable to administration of apoaequorin.

Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health. Apoaequorin is included in the dietary supplement Prevagen. It is used to improve mild memory loss associated with aging.

To get more information on the study, please visit the journal of Food and Chemical Toxicology. To get more information on apoaequorin, please visit the Prevagen website.

About Quincy Bioscience

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin focused on the discovery, development and commercialization of novel technologies to support good health in aging. The company’s products focus on supporting memory and cognitive health. Quincy Bioscience is set apart by its cutting-edge applications of the protein apoaequorin, which is breaking new ground in the area of brain health.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10765048.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
2. New measuring techniques can improve efficiency, safety of nanoparticles
3. Interim Clinical Trial Results Confirm Safety of Renadyl™, a Probiotic Dietary Supplement for the Support of Healthy Kidney Function
4. Targeted antibacterial agent rapidly created in response to serious food safety pathogen
5. Notre Dame paper examines nanotechnology-related safety and ethics problem
6. New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
7. Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway
8. OrbusNeichs Combo Dual Therapy Stent™ Demonstrates Favorable Clinical and Safety Outcomes at 12-Month Follow-Up
9. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
10. New Epidemiological Data Provide Additional Safety Evidence for Lantus®
11. Produce Safety Researchers Awarded by ABC Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... March 31, 2016   ... or the "Company") LegacyXChange is excited to ... its soon to be launched online site for trading ... ) will also provide potential shareholders a sense ... technology to an industry that is notorious for fraud. ...
Breaking Biology News(10 mins):